The FDA de­cides to hold an ex­pert pan­el re­view of Vas­cepa af­ter all — and Amarin shares tank on un­ex­pect­ed de­lay

Mark your cal­en­dars for No­vem­ber 14.

Af­ter slow­ly and cau­tious­ly rais­ing its hopes to the point where com­pa­ny ex­ecs be­lieved an Ad­Com on its sup­ple­men­tal la­bel for Vas­cepa was “un­like­ly,” the biotech put out word late Thurs­day that the FDA has pen­cilled in an ex­pert pan­el meet­ing for them in mid-No­vem­ber.

And in­vestors — who were grow­ing in­creas­ing­ly warm to the idea that the com­pa­ny could be on a cake­walk to a cru­cial, and po­ten­tial­ly block­buster, ap­proval on the Sep­tem­ber 28 PDU­FA date — pan­icked. Shares $AM­RN plunged 22% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER